Increased serum chemerin concentration in patients with chronic pancreatitis

Adrych, Krystian; Stojek, Magdalena; Smoczyński, Marian; Śledziński, Tomasz; Sylwia, Szrok-Wojtkiewicz; Świerczyński, Julian

doi:10.1016/j.dld.2011.06.020

Cited by 35 publications

(17 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This attracts other immune cells to the site of inflammation and intensifies their adhesion. 8 The increased plasma chemerin concentration was observed in patients with rheumatoid arthritis, ulcerative colitis and Crohn's disease, psoriasis, chronic pancreatitis and liver diseases, [9][10][11][12][13] and it positively correlated with inflammatory markers such as C-reactive protein, TNF-a, Il-6. 14 It is also commonly considered that chemerin decreases the rate of glucose uptake and impairs the insulin tissue sensitivity.…”

Section: Introductionmentioning

confidence: 99%

High serum chemerin level in CKD patients is related to kidney function, but not to its adipose tissue overproduction

Blaszak¹,

Szołkiewicz

Sucajtys-Szulc

et al. 2015

Renal Failure

Self Cite

View full text Add to dashboard Cite

Chemerin is an adipokine modulating inflammatory response and affecting glucose and lipid metabolism. These disturbances are common in CKD. The aim of the study was: (a) to evaluate circulating chemerin level at different stages of CKD; (b) to measure subcutaneous adipose tissue chemerin gene expression; (c) to estimate the efficiency of renal replacement therapy in serum chemerin removal. 187 patients were included into the study: a) 58 patients with CKD; (b) 29 patients on hemodialysis; (c) 20 patients after kidney transplantation. 80 subjects constituted control group. Serum chemerin concentration was estimated by ELISA. The adipose tissue chemerin mRNA level was measured by RT-qPCR. The mean serum chemerin concentration in CKD patients was 70% higher than in the control group (122.9 ± 33.7 vs. 72.6 ± 20.7 ng/mL; p < 0.001) and it negatively correlated with eGFR (r = -0.71, p < 0.001). The equally high plasma chemerin level was found in HD patients and a HD session decreased it markedly (115.7 ± 17.6 vs. 101.5 ± 16.4 ng/mL; p < 0.001). Only successful kidney transplantation allowed it to get down to the values noted in controls (74.8 ± 16.0 vs. 72.6 ± 20.7 ng/mL; n.s.). The level of subcutaneous adipose tissue chemerin mRNA in CKD patients was not different than in patients of the control group. The study demonstrates that elevated serum chemerin concentration in CKD patients: (a) is related to kidney function, but not to increased chemerin production by subcutaneous adipose tissue, and (b) it can be efficiently corrected by hemodialysis treatment and normalized by kidney transplantation.

show abstract

Section: Introductionmentioning

confidence: 99%

High serum chemerin level in CKD patients is related to kidney function, but not to its adipose tissue overproduction

Blaszak¹,

Szołkiewicz

Sucajtys-Szulc

et al. 2015

Renal Failure

Self Cite

View full text Add to dashboard Cite

show abstract

“…Also, increased circulating chemerin levels were found in many systemic inflammatory diseases. Main examples include Crohn's disease, ulcerative colitis [Weigert et al 2010b], chronic renal disease [Yamamoto et al 2010;Pfau et al 2010;Rutkowski et al 2012], liver diseases [Kukla et al 2010;Yilmaz et al 2011], chronic pancreatitis [Adrych et al 2012], pre-eclampsia [Stepan et al 2011] and polycystic ovary syndrome [Tan et al 2009]. Pfau and colleagues have shown that chemerin is an independent predictor in patients on chronic hemodialysis.…”

Section: Role Of Chemerin In Inflammation and Its Relationship With Smentioning

confidence: 99%

Chemerin as an independent predictor of cardiovascular event risk

İnci

Aksan

Doğan

2016

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Currently, coronary artery disease (CAD) is considered a major ailment in humans with widespread prevalence. CAD also accounts for high mortality rates around the world that involves several known risk factors. Chemerin is a novel adipokinine that is associated with inflammation and adipogenesis. Furthermore, experimental and clinical data indicate that localized as well as circulating chemerin expression and activation are elevated in numerous metabolic and inflammatory diseases including psoriasis, obesity, type 2 diabetes, metabolic syndrome and cardiovascular disease. Chemerin is accepted as being a strong marker because the serum chemerin levels are increased in a CAD condition. However, the chimeric characteristics of chemerin have not been fully investigated. Although chemerin is known to be responsible for CAD development among other factors, authors still investigate it at the marker level. This review focuses on chemerin expression, processing, biological function and relevance to human diseases, and on the role of chemerin in the maintenance of a cardiovascular disease.

show abstract

“…Chemerin cleaves into different fragments with pro-or anti-inflammatory actions. [23][24][25][26][27][28][29] Plasma chemerin is increased in chronic inflammatory diseases [23][24][25][26][27] and levels of chemerin correlate with levels of the proinflammatory cytokines, such as tumor necrosis factor (TNF-α), interleukin (IL-6), and C reactive protein. 23,28 Chemerin, through ChemR23, 29 has also been shown to have anti-inflammatory effects in vascular cells through processes that involve protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) signaling and nitric oxide production.…”

Section: Hypertensionmentioning

confidence: 99%

Chemerin Regulates Crosstalk Between Adipocytes and Vascular Cells Through Nox

et al. 2015

View full text Add to dashboard Cite

Adipocytes produce adipokines, including chemerin, a chemoattractant that mediates effects through its ChemR23 receptor. Chemerin has been linked to endothelial dysfunction and vascular injury in pathological conditions, such as obesity, diabetes mellitus, and hypertension. Molecular mechanisms underlying this are elusive. Here we assessed whether chemerin through redox-sensitive signaling influences molecular processes associated with vascular growth, apoptosis, and inflammation. Human microvascular endothelial cells and vascular smooth muscle cells were stimulated with chemerin (50 ng/mL). Chemerin increased generation of reactive oxygen species and phosphorylation of mitogen-activated protein kinases, effects that were inhibited by ML171, GKT137831 (Nox inhibitors), and N-acetylcysteine (reactive oxygen species scavenger). Chemerin increased mRNA expression of proinflammatory mediators in vascular cells and increased monocyte-to-endothelial cell attachment. In human vascular smooth muscle cells, chemerin induced phosphorylation of mitogen-activated protein kinases and stimulated proliferation (increased proliferating cell nuclear antigen expression [proliferation marker] and BrdU incorporation [proliferation assay]). Chemerin decreased phosphatidylinositol 3-kinase/protein kinase B activation and increased TUNEL-positive human vascular smooth muscle cells. In human microvascular endothelial cells, chemerin reduced endothelial nitric oxide synthase activity and nitric oxide production. Adipocyte-conditioned medium from obese/diabetic mice (db/db), which have elevated chemerin levels, increased reactive oxygen species generation in vascular smooth muscle cells, whereas adipocyte-conditioned medium from control mice had no effect. Chemerin actions were blocked by CCX 832, a ChemR23 inhibitor. Our data demonstrate that chemerin, through Nox activation and redox-sensitive mitogen-activated protein kinases signaling, exerts proapoptotic, proinflammatory, and proliferative effects in human vascular cells. These findings elucidate some molecular mechanisms through chemerin, which is increased in obesity, whereby adipocytes may influence vascular function. We identify chemerin as a novel vasoactive adipokine, which may be important in obesity-related vascular injury.

show abstract

Increased serum chemerin concentration in patients with chronic pancreatitis

Cited by 35 publications

References 40 publications

High serum chemerin level in CKD patients is related to kidney function, but not to its adipose tissue overproduction

High serum chemerin level in CKD patients is related to kidney function, but not to its adipose tissue overproduction

Chemerin as an independent predictor of cardiovascular event risk

Chemerin Regulates Crosstalk Between Adipocytes and Vascular Cells Through Nox

Contact Info

Product

Resources

About